Connect your AI

aTyr Pharma ATYR Non-Controlling Interests

Non-Controlling Interests at other companies

Gyre Therapeutics, Inc.GYRE

$35.68M-1.4%

BridgeBio PharmaBBIO

$10.44M+4.8%

Other financials

Income statement

Revenue-—

Operating income-$11.4M+27.5%

Net income-$10.8M+27.5%

EPS (diluted)-$0.11+35.3%

Balance sheet

Cash & equivalents$10.0M-3.4%

Total debt$12.3M-9.2%

Total equity$57.9M-22.8%

Total assets$79.7M-18.1%

Cash flow

Operating cash flow-$12.5M+18.8%

CapEx$138.0K—

Free cash flow-$12.7M+17.9%

Valuation

Market cap$54.88M-88.2%

Enterprise value$57.17M—

P/S288.8×—

Profitability

Operating margin-40,856.3%+28,833pp

Net margin-39,009.5%+29,653pp

FCF margin-32,664.7%+4,018pp

Returns & leverage

Return on equity-105.3%+50.6pp

Debt / equity0.2×0.0×

Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's non-controlling interests.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is aTyr Pharma's non-controlling interests?: aTyr Pharma (ATYR) reported non-controlling interests of -$193K in Q1 2026.
How has aTyr Pharma's non-controlling interests changed year-over-year?: aTyr Pharma's non-controlling interests decreased by 2.7% year-over-year, from -$188K to -$193K.
What is the long-term trend for aTyr Pharma's non-controlling interests?: Over 5 years (2020 to 2025), aTyr Pharma's non-controlling interests has grown at a 3.0% compound annual growth rate (CAGR), from -$166K to -$192K.
What does non-controlling interests mean?: Equity attributable to minority shareholders in subsidiaries not fully owned by the parent — their proportional claim on subsidiary net assets.